Mend announced today that Control Glucose, an evidence-based nutrapharma product designed to support blood sugar health, is now available to practitioners nationwide through Fullscript.
Over the past 30 years sugar consumption has steadily increased, posing a significant threat to public health worldwide, including surgical complications and delayed recovery.
The average American now consumes more than ten times the recommended daily allowance. Insufficient access to healthcare and education exacerbates the problem, particularly in low-income regions where resources for prevention and management are limited.
Mend Control Glucose contains a unique combination of compounds that have been studied in a dozen plus randomized placebo-controlled trials for their effects on blood sugar and A1C.
Through its own pilot randomized trial and in-home consumer use studies on the final formulation, mend has supported the results of the prior clinical studies showing statistically and clinically significant impact.
“Our pilot RCT and consumer studies have provided initial validation of this product and the benefits to blood sugar stabilization and management” says mend Chief Science Officer Dr. Kim Biederman, “we’re continuing to build the scientific dossier supporting this preventative product as an effective approach for healthy carbohydrate metabolism, hunger management, and stable blood sugar levels.”
Urgent action is imperative to address this crisis, emphasizing the importance of lifestyle modifications, new interventions, enhanced public health initiatives, and equitable access to healthcare services to mitigate the burden of high blood sugar related disorders on individuals and societies globally.
Practitioners across the United States can access Mend through Fullscript and implement the tool as deemed clinically appropriate for their patient populations.
